X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Freya will advance the clinical development of its lead drug candidate, FB101, an investigational vaginal microbial immunotherapeutic, for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART).
Lead Product(s): FB101
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FB101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $38.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 12, 2023
Details:
FB101, is an investigational vaginal microbial immunotherapeutic, which is investigated for the treatment of Women with Asymptomatic Vaginal Dysbiosis.
Lead Product(s): FB101
Therapeutic Area: Infections and Infectious Diseases Product Name: FB101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
